Revumenib: all 23 studies that test it
Page 1 of 1. Open to participants first (18), then studies with results posted, then the rest; newest registration first within each.
- Trial of Revumenib Plus FLA Chemotherapy for Children With Relapsed or Refractory NUP98-rearranged AML."Not yet recruitingNCT07686107Phase 2
- Testing Blinatumomab With or Without Revumenib in Patients With B-cell Acute Lymphoblastic Leukemia With a Genetic Change Requiring More TreatmentNot yet recruitingNCT07636564Phase 2
- Revumenib, Azacitidine, and VENetoclax in Newly Diagnosed KMT2A-Rearranged AMLNot yet recruitingNCT07605949Phase 2
- Menin-Inhibitor Targeted Maintenance in AMLNot yet recruitingNCT07563010Phase 2
- A Study of Revumenib and Mezigdomide in People With LeukemiaRecruitingNCT07356154Phase 1/2
- A Phase IB Trial of Subcutaneous Blinatumomab in Combination With Revumenib for Patients With KMT2A-rearranged Acute Lymphoblastic LeukemiaNot yet recruitingNCT07283640Phase 1
- Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 MutationRecruitingNCT07211958Phase 3
- Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AMLRecruitingNCT06652438Phase 3
- Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell TransplantRecruitingNCT06575296Phase 1
- Revumenib in Combination With 7+3 + Midostaurin in AMLRecruitingNCT06313437Phase 1
- A Multi-Site Break Through Cancer Trial: Phase II Study Investigating Dual Inhibition of BCL2 and Menin in AML MRD Using the Combination of Venetoclax and RevumenibRecruitingNCT06284486Phase 1/2
- A Phase II Study of the Menin Inhibitor Revumenib in Leukemia Associated With Upregulation of HOX GenesRecruitingNCT06229912Phase 2
- SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 MutationRecruitingNCT06222580Phase 1
- Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid LeukemiaRecruitingNCT06177067Phase 1
- A Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations DiseaseRecruitingNCT05886049Phase 1
- A Phase I-II Study Investigating the All-Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)RecruitingNCT05360160Phase 1/2
- A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 MutationRecruitingNCT04065399Phase 1/2
- Study of Biomarker-Based Treatment of Acute Myeloid LeukemiaRecruitingNCT03013998Phase 2/3
- Evaluation of Revumenib in Participants With Colorectal Cancer and Other Solid TumorsTerminatedNCT05731947Phase 1/2Results posted
- A Study to Find the Highest Dose of SNDX-5613 (Revumenib) as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, and Mixed Phenotype Acute LeukemiaWithdrawnNCT07498465Phase 1
- A Phase Ia/Ib Trial of Revumenib Combined With Cytarabine, Daunorubicin, and Gemtuzumab Ozogamicin (GO) in Frontline and Relapsed /Refractory Pediatric Acute Leukemia PatientsWithdrawnNCT07052994Phase 1
- A Study of Revumenib in Combination With Intensive Chemotherapy in Participants With Acute Myeloid LeukemiasActive, not recruitingNCT06226571Phase 1
- Study of Radiolabeled Revumenib in Adults With Acute LeukemiaCompletedNCT05406817Phase 1